ImmunityBio Inc.’s (IBRX) N-803 plus Bacillus Calmette-Guérin, proposed for use in high-risk non-muscle-invasive bladder cancer, awaits the FDA decision on April 23, 2024.To be specific, N-803 plus Bacillus Calmette-Guérin (BCG) is proposed for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (CIS) with or without Ta or T1 disease. BCG is the standard of care for bladder cancer patients. Ta and T1 are classifications used to categorize non-muscle invasive bladder cancer according to their growth pattern and depth of invasion.This is the company’s second attempt to secure FDA approval for N-803.The U.S. regulatory agency had declined to approve N-803 plus BCG last May citing issues with the FDA's inspection of the company's third-party contract manufacturers prior to licensing.IBRX is currently (Mar.28, 2024) trading at $5.39, down 0.37%.